Tactile Systems Technology, Inc. announced on October 2, 2024, the commercial availability of Nimbl, its next-generation pneumatic compression platform, throughout the United States for the treatment of upper extremity lymphedema.
Nimbl received U.S. Food & Drug Administration (FDA) 510(k) clearance in June 2024 and Pricing, Data Analysis, and Coding (PDAC) approval from the Centers for Medicare & Medicaid Services (CMS) in September 2024. The company plans to make Nimbl commercially available for patients with lower extremity conditions in the coming months.
The new device is 68% lighter, 40% smaller, and uses 33% less hosing than the company’s current basic pneumatic compression device, making it the smallest of its kind. Nimbl also offers connectivity to the Kylee™ digital application, allowing patients to track usage and symptoms, which enhances patient adherence and care coordination.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.